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An intracellular staining procedure for the cytoskeletal marker, glial fibrillary 
acidic protein of astrocytes, has been developed which allows flow cytometric 
phenotyping of astrocytes within complex mixttires of glial cells. Employing this 
technique, we show here that measles virus infection of rat mixed gl.ial cell 
cultures results in a rapid augmentation of major histocompatibility complex 
(MHC) dass I and ICAM-1 on the majority of astrocytes in culture. MHC class I 
Ievels are increased on macrophages/microglia but ICAM-1 expression is not 
normally affected on this cell type. Some MHC dass II induction is also observed 
after virus infection but only on astrocytes. A type-I interferon (IFN)-inducible 
protein, Mx, was identified in cultured glial cells after infection. Qualitatively 
comparable MHC dass I and ICAM-1 enhancement after addition of type-I IFN, 
supports the conclusion that this cytokine(s) releasedas a result ofvirus infection, 
is responsible for alterations in the expression of molecules on glial cells, that are 
involved in T cell recognition. Astrocytes after viral infection were more 
susceptible to alloantigen-specific cytotoxic T lymphocytes and cytotoxic T 
lymphocyte activity was substantially reduced in the presence of mAb specific for 
MHC class I, ICAM-1 and LFA-1 but not MHC dass II. The relevance of these 
findings toT cell recognition of virus-infected cells in the centrat nervaus system is 
discussed. 
1 Introduction 
Measles virus (MV) is a common human pathogen respon-
sible for a range of diseases from acute MV infection of 
childhood through to severe infections of the central 
nervous system (CNS). Within this Iatter category, disease 
types vary from acute measles encephalitis to subacute 
sclerosing panencephalitis in which onset of clinical disease 
generally occurs many years after recovery from normal 
acute MV infection (reviewed in [1]). An effective immu-
nological response to such infections of the CNS is 
undoubtedly complex and hampered by the relative Iack of 
MHC [2] and adhesion molecule expression (such as 
ICAM-1, [3]) in this tissue. Nevertheless, the immune 
system under normal circumstances apparently copes with 
the vast majority ofviral infections in the CNS (reviewed in 
[4]). 
How is this effective immune surveillance achieved? First, 
it is possible that antigenic peptide is displayed on the 
Iumina) face of brain vascular endothelial cells. These cells 
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are constitutively MHC class J+ and so, at least for 
virus-specific CDS+ T cel1s, this could be a point of 
recognition. LCMV-derived peptides for example, are 
almost certainly recognized by CD8+ T cells at this site [5). 
Second, there is now good evidence to suggest that the 
brain is patrolled by activated T cells nonspecifically cross-
ing the blood-brain barrier [6, 7]. However, Tcell recogni-
tion of viral peptides in the context of MHC dass I or 
dass li molecules is unlikely to occur readily in the 
parenchyma of the CNS. This is an important caveat as it is 
cells such as astrocytes, oligodendrocytes and neurons that 
are the foci of virus infection in subacute sclerosing 
panencephalitis for example [1]. Much attention has been 
focused on the ability of certain inflammatory cytokines, in 
particular IFN-y and TNF-a, to induce and up-regulate 
MHC and ICAM-1 expression on glial cells [7, 8] but the 
presence of these factors in the CNS would indicate that an 
inflammatory process has already been initiated. In the 
absence of such inflammation, which is a far more Jikely 
situation early after the virus has entered the CNS, 
inflammatory cytokine-mediated up-regulation of MHC 
and JCAM-1 expression on glial cells cannot be considered 
a viable mechanism for induction of conditions that would 
enable the infected cell to be recognized by T lympho-
cytes. 
For virus infections of the CNS, one possibility is that the 
virus itself directly or indirectly induces or enhances the 
expression of cell-surface molecules important for T cell 
recognition. A number of reports have already been made 
regarding the up-regulation of MHC dass I on a variety of 
infected cell types ([9-12], reviewed in [13]) and also MHC 
class II induction on otherwise negative cells, including 
astrocytes [11, 12, 14]. The mechanisms underlying the 
alteration of MHC expression in virus-infected cells are 
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unclear. In the present study we have examined the 
augmentation of MHC antigens and the adhesion molecule 
ICAM-1 on mixed glial cells infected in vitro with MV. The 
results clearly indicate that virus infection alone is sufficient 
to consistently increase astrocyte MHC class I and ICAM-1 
expression and that these phenotypic changes are probably 
mediated by MV-induced release of type-1 IFN. 
2 Materials and methods 
2.1 Animals 
Full-term pregnant rats and 8- to 10-week-old female rats 
were obtained from Zentralinstitut für Versuchstierzucht, 
Hannover, FRG. All animals were SPF and from the Lewis 
(LEW, RT1 1) and BDII {RT1 u) strains. 
2.2 Monoclonal and polyclonal antibodies 
Mouse mAb were: MRC OX1 (anti-rat CD45; leukocyte 
common antigen, [15]), MRC OX6 (anti-rat monomorphic 
MHC dass II, RT1B (1-A), [16]), MRC OX18 {anti-rat 
monomorphic MHC class I, RT1A, [17]), MRC OX21 
(anti-human C3bi and not rat cells, [18]), MRC OX42 
(anti-rat CDllb/c, [19, 20]),WT.1 (anti-rat CDlla, LFA-1, 
[20]), 1A29 (anti-rat CD54, ICAM-1, [21]), mGalC (anti-
galactocerebroside, [22]) and F227 (anti-MV nucleocapsid 
(N) protein, generated by Uwe Liebert of this Institute). 
MRC OX21 and F227 tissue culture SN were provided by 
Don Mason, Oxford, GB and by Uwe Liebert, respectively. 
All other mAb were prepared as tissue culture SN or ascites 
fluid from hybridomas obtained from Alan Williams, 
Oxford, GB (OX1,-6,-18,-42) and B. Ranscht (mGalc). 
MRC OX6, MRC OX18, 1A29 and WT.1 IgG were purified 
from ascites fluid by standard procedures. MRC OX6 and 
MRC OX18 IgG were biotinylated as described [23]. 
Rahbit anti-glial fibrillary acidic protein (GFAP) was from 
Dakopatts (Hamburg, FRG) and normal rabbit IgG from 
Dianova (Hamburg, FRG). AP5 (rabbit anti-mouse Mx 
protein that strongly binds rat Mx-1, [24]) was kindly 
provided by Dr. Otto Haller, Institute for Virology, Frei-
burg, FRG. FITC-conjugated rat anti-mouse IgG, TRITC-
conjugated goat anti-rabbit IgG, PE-conjugated donkey 
F(ab')2 anti-rabbit IgG (pre-absorbed against mouse and 
rat Ig) and PE-conjugated streptavidin were from Dia-
nova. 
2.3 Ceß lines, cytokines and miscellaneous reagents 
Mycoplasma-free African green monkey kidney fibroblast 
(CV1) cells were obtained from the European Collection of 
Animal Cell Cultures, Porton Down, GB. A GFAP- isolate 
of the human glioma (D-54) cellline [25] was obtained from 
R. Brinkmann of this Institute. Both lines were maintained 
in DMEM-5% FCS. riFN-y was kindly provided by Dr. P. 
H. Van der Meide, Rijswijk, The Netherlands and human 
rTNF-a was from Boehringer, Ingelheim, FRG. Purified 
rat type-1 IFN (mostly IFN-a, some IFN-ß), n-octyl-
ß-o-glucopyranoside and BSA were from Sigma Chemical 
Company, Deisenhofen, FRG. 
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2.4 Virus preparation 
MV (Edmonson strain) was produced and titrated on CV1 
cells by standard procedures. Additionally, mock-infected 
CV1 cells were incubated at 33 oc for 3 days to produce 
control SN. 
2.5 Glial cell preparation and experimental procedures 
Primary enriched astrocyte cultures consisting of90%-95% 
GFAP+ cells with < 2% microglia present (as defined by 
CD45 [26] and MRC OX42 [19, 26] expression), were 
prepared from the meninges-stripped cerebrallobes of 1- to 
2-day-old Lewis strain rats as described [27]. Cells were 
harvested from flasks and either seeded into wells of 6-well 
plates, directly stained for FCM or seeded into wells of 
24-well plates containing glass coverslips to enable fluores-
cence microscopic analysis. Mixed glial cultures were 
prepared as above but were seeded at high density (usually 
around eight times that used to prepare enriched astrocyte 
cultures) directly into wells of 6-well or 24-well plates and 
were used within 10 days of culture establishment. The 
major cell types constituting these latter cultures are de-
scribed in Sect. 3. Forvirus infection, medium was replaced 
with 1 ml (6-well plates) or 100 ~~ {24-well plates) mock-
infected CV1 SN or MV at a concentration of 3 x 106-5 X 
106 PFU/ml ( corresponding to a multiplicity of infection of 
between 1 and 3) for 1 hat 37 °C, then the SN were removed 
and fresh medium was added. This is designated day 0. In 
most experiments, virus or mock SN were added as above to 
these same cell cultures 24 h later and again 48 h later. 
After a further 24 h, the cells were usually harvested for 
flow cytofluorographic analysis or coverslips stained for 
fluorescence microscopic analysis. rTNF-a, riFN-y or type-
I IFN at a final concentration of 10 U/ml were added to glial 
cell cultures alone or together with mock or virus-contain-
ing supernatants (rTNF-a only) as detailed in Sect. 3. 
2.6 Cell staining 
2.6.1 Fluorescence microscopy 
Cells adherent to glass coverslips were washed, fixed for 
10 min with 3% paraformaldehyde and permeabilized by 
treatment with 0.5% Triton X-100 for 5 min. After blocking 
with 10% BSA in 0.025 M Tris buffer for 15 min antibodies 
aginst Mx, GFAP or MV and appropriate FITC-or TRITC-
coupled second antiborlies were added. Coverslips were 
mounted in glycerol and viewed with a Leitz (Giessen, 
FRG) Aristoplan fluorescence microscope. 
2.6.2 Internat labeling and Dow cytoßuorographic 
analysis 
Cells were removed from culture flasks or 6-well plates by 
standard trypsin!EDTA treatment and washed in cold PBS 
0.2% BSA 10 mM sodium azide. For extracellular staining, 
unlabeled mouse mAb (negative control ortest) was added 
to samples of 3 x 105-5 x 105 cells for at least 30 min on ice 
then the cells washed, resuspended in FITC-conjugated rat 
anti-mouse Ig and incubated on ice for a further 30 min. 
After washing, the surface Iabeted cells were assessed 
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directly or permeabilized employing a modification of a 
method described by Hallden et al. [28]. Each aliquot of 
cells was resuspended in 400 f.tl ice-cold formaHn [0.5% 
(v/v) in PBS without Ca2+ and Mg2+] and incubated for 
30 min on ice. After washing, the cells were resuspended in 
500 f.tl n-octyl-ß-o-glucopyranoside ( 4 mg/ml in 0.15 M 
PBS), incubated for 7 min at room temperature then 
washed and pelleted. The cells were resuspended in 25 ~-tl of 
10% BSA in 0.025 M Tris buffer and incubated for 15 min 
on ice. Tothis was added 25 f.tl rabbit IgG anti-GFAP or as a 
control, normal rabbit IgG at the same concentration and 
incubated for 45 min on ice. After washing, the cells were 
resuspended in 50 f.tl PE-conjugated donkey anti-rabbit 
IgG diluted in PBS 1% BSA 10% normal rat serum 10% 
normal mouse serurn and incubated for 1 h on ice. After 
further washes, 104 live gated events were analyzed on a 
FACScan™ (Becton Dickinson, Heidelberg, FRG). 
2. 7 CTL assays 
Alloreactive BDII CTL against LEW were generated in an 
MLR by mixing and incubation for 5 days 2.5 x 105 
irradiated LEW LN stimulator ceJls with 5.0 x 105 
respander BDII LN cells per U-bottom weil. Target cells 
were either LEWor BDII Con A blasts or LEW astrocytes 
which bad been mock-or virus infected as described above 
and recovered 72 h after initial ( dO) infection. 51Cr-labeled 
target cells were pre-incubated for 40 min on ice either in 
medium alone or with blocking mAb (see Sect. 3), added to 
titrated CTL effector cells in 96-well V-bottom plates and 
incubated for 5 h at 37 oc. Data shown is percent of total 
release after subtraction of spontaneaus release. With T cell 
blast targets, spontaneaus release was < 30% while with 
astrocyte targets, it varied between 20% and 40%. 
3 Results 
3.1 lotemal labeling of astrocytes 
The cytoskeletal protein, GFAP, is the most reliable marker 
for astrocytes bothin vivo and in vitro [29] but because this 
is an intracellular molecule, detection requires permeabil-
ization of the cell membrane. The protocol used here offers 
a number of advantages over other standard fixation/per-
meabilization procedures. Fig. 1 b illustrates the low Ievel 
of nonspecific staining by normal rabbit lgG (control), 
while addition of anti-GFAP produced a strong positive 
shift in around 90% of the cells. A comparable figure for 
GFAP+ cells in this population was obtained by standard 
immunofluorescence microscopy. Untreated astrocyte.s 
(Fig. 1 a) were not stained with anti-GFAP. Other proce-
dures tested, including paraformaldehyde fixation and 
permeabilization with Triton X-100, were unsatisfactory. 
The same scatter shift (Fig. 1 b) was seen after 0.5% 
formalin fixation alone (not shown). 
3.2 Astrocyte detection in cell mixtures 
To study the effects of MV infection on glial cell expression 
of MHC and adhesion molccules in vitro, mixed glial 
populations were generally used rather than enriched 
astrocytes to more closely mirnie the in vivo situation. 
forward scatter fluorescence 
Figure 1. GFAP staining of astrocytes for FCM. Enriched astro-
cyte cuJtures were stained for GFAP (solid line) or an equivalent 
concentration of normal rabbit IgG (dashed line). (a) Unfixed, 
non-permeabilized; (b) 0.5% formaJin fixed, n-octyl-ß-D-glucopy-
ranoside permeabilizcd as per Sect. 2.6. 
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Figure 2. Astrocyte and microglia content of mixed glial cultures 
revealed by two-color FCM and internal staining. ( a-d) Cells were 
stained exactly as described in Sect. 2.6 for surface markers (MHC 
dass I and CD45 with MRC OX21 as negative control) then fixed 
and permeabilized and stained internally [GFAP or rabbit (Rb) 
IgG as negative control). (e, f) Cells were double surface stained 
for CD45 or CDllb/c and MHC dass I, the latter detected with 
biotinylatcd MRC OX18 mAb and PE-streptavidin. 
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Table 1. Detection of astrocytes in cell mixtures3 > 
Sample: 2 3 
Stained input Astrocytes (%) 30 50 70 
population D-54 cells (%) 70 50 30 
Positive cells by GFAP+ (%) 24 53 62 
FCM GFAP- (%) 76 47 38 
a) Cells from enriched rat astrocyte cultures and GFAP- D-54 
glioma cells were mixed in the proportions shown, then fixed, 
permeabilized and stained for GFAP as described in Sect. 2.6 
and analyzed by FCM. 
Table 1 first i11ustrates that GFAP+ rat astrocytes could be 
accurately quantitated by FCM when mixed with GFAP-
(054) cells. Fig. 2 dearly demonstrates the versatility of 
this method for detection of Subpopulations of cells in a 
normal mixed glial culture 8 days after establishment. 
Cells were cultured in the presence of FCS and so, as 
expected [29], cell differentiation was driven in the direc-
tion of astrocytes. Astrocytes in situ are MHC dass I- or 
express extremely low Ievels of this molecule [2] but 
become MHC dass J+ during cell culture [30]. The GFAP+ 
cells shown in Fig. 2 c split into MHC dass J+ (around 50%) 
and class I- (around 20%) populations. lt is likely that the 
MHC dass I- GFAP+ cells are the more recently differen-
tiated ones. The MHC dass I+ GFAP- cells (around 25%) 
are mostly M<I>/microglia (15-18%) which are CD45+ 
(Fig. 2 d and e) and CDllbfc+ (Fig. 2 f). There are two 
populations that remain undcfined. Around 5% of the cells 
are both MHC dass I- and GFAP- (Fig. 2 c, box 3). There 
are also some cells that are MHC dass J+ (Fig. 2 c, box 4) 
but arenot M<I>/microglia, at least as defined by CD45 and 
CDllb/c staining. Some of these cells could be oligoden-
drocytes but generally, < 5% galactocerebroside-positive 
cells (oligodendrocytes) were detected in these cultures. 
3.3 MV infection augments expression of MHC class I 
and ICAM-1 on astrocytes 
Within 4 h ofvirus addition on day 0 to mixed glial cultures, 
the majority of cells were infected, as determined by 
immunofluorescence microscopic detection of cytoplasmic 
viral nucleocapsid protein. By 24 h, generally < 10% of the 
cells were infected by this same criterion and on the basis of 
cell morphology, the majority of these were astrocytes. In 
view of previous sturlies from this laboratory on the ability 
of both infectious and non-infectious viral partides to 
induce or enhance MHC expression on glial cells in vitro 
(11], live virus was usually added on day 1 and day 2 
although this did not result in an increase in the number of 
productively infected cells. 
Double staining of infected cultures showed that MHC 
class I expression was significantly enhanced in both 
GFAP+ (astrocyte, Table 2) and GFAP- (microglial) pop-
ulations. The magnitude of this increase was similar for all 
populations. In contrast, any induction of MHC dass II was 
virtually restricted to GFAP+ astrocytes (see below). 
ICAM-1/GFAP expression divided the mixed glial cultures 
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Table 2. Incrcascd astrocyte MHC dass I and ICAM-1 expression 
after MV infection3 > 
MHC class I 
MHC class II 
ICAM-1 
Non-infected Day 1 
(day 0) 
Day 2 
65b) (239) 
2 (156) 
64 (420) 
74 (386) 90 (849) 
4 (113) 10 (166) 
61 (398) 83 (571) 
Day 3 
96 (788) 
7 (206) 
90 (465) 
a) Uninfected cells from mixed glial cultures were examined for 
cell surface phenotype on day 0 of the experiment. MV was 
added to mixed glial culturcs for 1 h on day 0 only and stained 
for FCM 24 h later (day 1), on day 0 and day 1 and examined 
24 h later (day 2) or on day 0, day 1 and day 2 and examined 
24 h later (day 3). 
b) Percentage positive GFAP+ cells prescnt within uninfccted or 
infected mixed glial cultures. Figures in parentheses are mean 
tluorescence intensity. These data are from a single experiment. 
MHC dass I and ICAM-1 Ievels shown here are highly repre-
sentative of other comparable experiments. Percentagc MHC 
dass n+ astrocytes was rarely higher than shown here and 
usually < 7% of cells were positive after infection. MHC dass Il 
fluorescence intensity Ievels were generally low and not 
enhanced by infection. 
into four populations almost identical to that seen with 
MHC dass 1/GFAP (Fig. 2c; see also Fig. 4 for ICAM-1 
expression). Unlike MHC dass I, however, MV infection 
only resulted in increased expression of ICAM-1 on 
astrocytes. Mean fluorescence intensity shifts for ICAM-1 
afterinfection in one experiment were: GFAP+ cells, 311 to 
465 and GFAP- (microglial) cells, 462 to 490. In some cases 
the latter cell population did not shift at all. Thus, the data 
in Table 2 show only the changes in phenotype of astrocytes 
present within these mixed gliaJ cultures. Enhanced MHC 
dass I expression occurs rapidly, being evident by day 1 and 
normally peaking on day 2. The magnitude of ICAM-1 
augmentation after MV infection is not as substantial, 
increases are not seen until day 2 and, like MHC dass I, 
ICAM-1 expression begins to reduce by day 3. 
MHC dass II expression on > 15% of astrocytes was 
detected only in a minority of cases and more typical results 
are given in Table 2 and its legend. Addition of TNF-a 
together with virus did not further increase the expression 
ofMHCclass I, MHCclass II or ICAM-1 (data not shown). 
Note that addition of low Ievels of IFN-y to our mixed glial 
cultures (10 U/ml or less) induced high Ievel expression of 
MHC dass II on both astrocytes and microglia ( data not 
shown). 
3.4 Expression of the intranuclear rat Mx protein and 
secretion of type-1 IFN 
The possible re]ease of type-I IFN by infected glial cells was 
investigated employing antibody recognizing rat Mx, a 
protein inducible by type-I IFN but not IFN-y [24, 31]. 
Fig. 3 and Table 3 show that Mx was induced in a high 
proportion of cells in mixed glial cultures after virus 
infection. In araund 30% of infected cells, Mx was not 
detected but was highly induced in the surrounding cells 
(Fig. 3 a). The remaining infected cells were also Mx+. Two 
additional points should be noted. First, transfer of SN 
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Table 3. Induction of Mx in mixed glial cells after MV infec-
tionnl 
Mock infection 
MV infection 
Non-infectcd Day 1 Day 2 Day 3 
(day 0) 
]bl 
1 
2 
54 
1 
60 
2 
51 
a) Uninfected cells from mixed glial cultures were examined for 
Mx on day 0 of the experiment. MV was added to mixed glial 
cultures for 1 h on day 0 only and stained for FCM 24 h later 
(day 1), on day 0 and day 1 and examined 24 h later (day 2) or 
on day 0, day 1 and day 2 and examined 24 h Iater (day 3). 
b) Shown are percentage strongly Mx+ cells within the total glial 
cell population. Data are typical of two other similar experi-
ments. 
from day 1 and day 2 infected cultures onto uninfccted glial 
cells resulted in comparable Ievels of Mx induction. No 
virus-infected cells could be detected in these recipient 
Figure 3. Mx+ cells in virus-infected cultures. Double staining for 
viral antigen and Mx was achieved by first staining with F227 
(anti-MV nucleocapsid) and FITC-anti-mouse IgG followed by 
addition of rabbit anti-rat Mx and TRITC-conjugated goat anti-
rabbit IgG. (a) MV-infected mixed glial culture showing a single 
virus-infected cell (cytoplasmic staining of viral nucleocapsid) 
surrounded by Mx+ cells which in this field are mostly astrocytes 
(nuclear staining). The infected cell is not Mx+ in this case. (b) 
Mock-infected glial cell culture stained as in (a) for MV nucleo-
capsid and Mx. 
cultures which is not surprising given previous studies [32] 
which found only very low Ievels (0.01-0.001 PFU/infected 
ceJl) of infectious virus present in glial cell SN obtained 
24-48 h post MV infection. Second, treatment of mixed 
glial cultures with 10 U/ml rat type-1 IFN induced a 
comparable increase in MHC class I and ICAM-1 expres-
sion on astrocytes but had no effect on MHC dass II 
expression. Moreover, as illustrated in Fig. 4, the cell 
populations responding to type-I IFN were similar to those 
that responded after virus infection as discussed above. 
Thus, type-I IFN increased MHC class I expression on aB 
cells in culture including M<l>/microglial cells (compare 
Fig. 4 a with 4 c where all populations shift to the right). In 
contrast, only "mature" GFAP+ ICAM-1 + cells (Fig. 4 b 
and 4d, box 2) revealed an increased ICAM-1 expression 
and the magnitude of this increase was relatively low as seen 
also after MV infection (Table 2). Mean fluorescence 
intensity of the main GFAP+ MHC dass I+ populations 
(box 2) are a, 174 and c, 572, and of the GFAP+ ICAM-1 + 
populations are b, 311 and d, 421. 
In view of these results, preliminary attempts were made to 
determine whether the presence of blocking anti-type-1 
IFN antibody would inhibit the augmentation of MHC 
class I and ICAM-1 following MV infection. Addition of 
polyclonal anti-rat type-I IFN to g1ial cultures treated with 
type-I IFN completely neutralized the MHC dass I and 
ICAM-1 enhancing effect of the cytokine. However, addi-
tion ofthe same concentration of antibody to virus-infected 
cultures reduced to some extent the magnitude of MHC 
class I and ICAM-1 augrnentation but did not completely 
eliminate it. The possible interpretations and implications 
of these studies are discussed below. 
3.5 Astrocytes from MV·infected cultures are more 
susceptible to MHC dass 1-restricted CTL 
To examine the functional impact of enhanced MHC class I 
and ICAM-1 Ievels on astrocytes, alloreactive CTL were 
generated and their ability to lyse enriched astrocytes 
derived from mock vs. infected cultures examined. The data 
shown in Fig·. 5 a (Exp. 1) is a typical outcome demonstrat-
ing that at lower E/T ratios, astrocytes from infected 
cultures were still lysed while those from mock-infected 
cultures were not. CTL activity was substantially reduced in 
the presence of 10 j..tg/ml mAb specific for MHC dass I and 
LFA-1 but not with this concentration of mAb against 
MHC dass II or ICAM -1 (Fig. 5 b). The inability of the 
1A29 mAb against rat ICAM-1 to block CfL activity was 
unexpected in view of the fact that this concentration of 
mAb prevents cell-cell adhesion in vitro [21]. In a subse-
quent experiment to test whether this was due to a 
concentration effect (Exp. 2), a variation on the enhanced 
killing of virus-infected astrocytes was observed. Percent 
specific releasewas very high and there was enhancement of 
killing compared with mock-infected astrocytes at both 
high and lower E/T ratios (Fig. 5 c). The important aspect, 
however, was that doubling the concentration of anti-
ICAM-1 mAb to 20 j..tg/ml resulted in effective CfL 
inhibition, whereas 20 j..tg/ml anti-MHC class li mAb still 
had no effect (Fig. 5 d). CfL specificity was tested aginst 
T cell blasts. Typical specific 51Cr release at a 1 : 50 ratio for 
syngeneic BDII blasts was < 1% and for allogeneic LEW 
blasts, around 40%. 
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Figure 4. Alteration in astrocyte and microglial cell MHC dass l 
and ICAM-1 expression after type-I IFN treatment. Mixed glial 
cells were left untreated ( a, b) or incubated for 48 h in the presence 
of 10 U/ml type-I IFN (c, d) then the cells stained for MHC dass I 
and ICAM-1. 
4 Discussion 
Increasing the expression Ievels of cell-surface molecules 
that are essential for T cell recognition of virus-infected 
cells is obviously a critical step in the development of 
effective antiviral immune responses in the CNS. As 
demonstrated here and elsewhere for MHC molecules 
[10-12, 14] and for the firsttime for ICAM-1 (Table 2), it is 
apparent that enhanced expression may result from the 
virus infection itself, rather than in response to inflamma-
tory cytokines. It is apparent moreover, that this has a 
functional impact in as much as an increased susceptibility 
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of astrocytes from infected cultures to MHC dass 1-
restricted CTL was consistently observed (Fig. 5). Yet the 
mechanisms by which cell surface molecule expression may 
be induced or augmented in situations such as that seen 
here, are not weil understood. 
There are at least three ways in which virus infection may 
influence the expression of cell surface molecules: ( a) direct 
effect of the virus. Possibilities here include a virus 
transactivating gene product that influences cellular genes 
contro1ling expression of surface antigens [33, 34]; (b) 
virus-induced release of factors such as type-I IFN that act 
in an autocrine fashion onto the producing cell and (c) as 
per mechanism 2 but also acting on other cells (13]. With 
regard to the MV-mediated MHC and ICAM-1 enhance-
ment observed here, there is as yet no evidence for the 
existence of a MV transactivating capacity. However, 
certain IFN-inducible genes have been shown tobe induced 
directly by double-stranded RNA [35] or intact virus [36]. 
This raises the possibility that RNA viruses like MV may 
directly up-regulate the expression of surface molecules 
such as MHC dass I in a similar way, particularly as there is 
significant sequence homology between the promoter 
regions of MHC dass I and type-I IFN genes [37]. To date, 
however, no direct evidence is available that such a 
mechanism is operating here. 
We believe that the presence of Mx in cultures infected with 
MV is a good indicator for the presence of type-I IFN and 
indeed, the SN transfer studies confirm that IFN bad been 
secreted. Moreover, this same cytokine when added to glial 
cultures was capable of modifying MHC dass I and ICAM-
1 expression (Fig. 4) in a comparable manner. Thus, it is 
likely that type-1 IFN is playing a centrat roJe in these 
experiments. Nevertheless, it is difficult to prove this 
mechanism unequivocally. As noted in Sect. 3, studies with 
blocking anti-IFN antibody did not effectively prevent 
MV-induced augmentation of surface molecule expression. 
On the one hand, this preliminary result could suggest that 
IFN is not involved and that MHC class I and ICAM-1 
enhancement, and even Mx induction, are directly 
mediated by virus via mechanisms akin to those discussed 
above. However, there are major limitations to these 
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inhibition studies. In particular, it is not clear how effec-
tively antibodies may neutralize autocrine Stimulation. For 
example, addition of high concentrations of anti-human 
IFN-ß antisera to MV-infected human glioma cells (which 
only secrete IFN-ß), reduces the amount of detectable 
Mx-A protein only by around 50% (S. Schneider-Schaulies, 
data not shown) and one can argue in this case either that 
the virus directly up-regulates Mx-A (for which there is no 
evidence), or that prevention of autocrine type-I IFN 
effects is lacking. We favor the latter of these two explana-
tions. In the present experiments, enhanced surface anti-
genexpressionwas observed on the majority of astrocytes 
in culture and yet, relatively few cells were still infected 
when the cells were analyzed at 24, 48 and 72 h. This could 
argue against the possibility of autocrine effects unless 
these were initiated within the first few hours after addition 
of virus when most cells were infected. Given the rapid 
appearance of Mx in virus-infected cultures (Table 3) and 
enhanced MHC dass I expression already by day 1 (Ta-
ble 2), it is probable that this did occur. Subsequently, there 
can be little doubt that many cells were further affected by 
soluble type-I IFN released from infected cells as evidenced 
by our observation of high Mx expression surrounding 
virus-infected cells (Fig. 3). 
Release of type-1 IFN by virus-infected ce11s does not 
readily explain the low Ievel induction of MHC dass Il on 
astrocytes observed in some of our experiments and in 
studies by others [11, 12, 14]. Neutralizing antiborlies have 
been used [11] to exclude the role of IFN-y in virus-
mediated induction of MHC dass II although, as with the 
present studies with anti-type-1 IFN antibodies, such an 
approach cannot entirely exclude autocrine effects. Nev-
ertheless, it is most unlikely that IFN-y could be responsible 
because typical cellular sources of IFN-y such as T lympho-
cytes and NK cells are absent and there is no evidence that 
astrocytes (or microglia) produce it. Moreover, addition of 
IFN-y to mixed glial cultures induced MHC dass II expres-
sion on both astrocytes and microglia, while after MV 
infection, only the former cell type became MHC dass n+ 
at a very low Ievel. It is notable that the Ievels of MHC 
dass II induction were less than that observed previously 
with MV in a similar system [11]. This may be explained by 
the high Ievels of type-I IFN in our cultures as this cytokine 
is reported to inhibit MHC dass II induction [38). 
Opinions are divided concerning the relative importancc of 
cytolytic CD4+ [39] or CD8+ (40] T Iymphocytes in the 
immunological control of MV infection. lt is now dear that 
peptides derived from internal MV structural proteins can 
be presented by both MHC dass I [41] and MHC dass II 
molecules [42] and MV appears relatively unusual, 
although not uniquc [43) in this respect. In rat models of 
CNS MV infection, there is evidence for a centrat role for 
both cytolytic CD8+ (44] as weil as CD4+ [45) Tcells in 
control of infection. Nevertheless, with regard to elimina-
tion of CNS-associated virus, it would appear from the 
present studies that MHC dass I is more likely to be 
enhanced on infected glial cells and in that sense, MHC · 
dass 1-restricted CTL should more readily be able to 
recognize the infected target cell. Furthermore, in general, 
it is difficult to induce MHC dass II in vivo on the typical 
target cells of MV in the CNS, such as astrocytes, neurons 
and oligodendrocytes although it is certainly possible that 
the low Ievels that are induced are sufficient to allow CD4 + 
T cell recognition. 
Mx-A + cells have recently been detected in association 
with virus-infected cells in CNS tissue obtained post-
martern from several subacute sclerosing panencephalitis 
patients (S. and J. Schneider-Schaulies, unpublished) indi-
cating the secretion of type-1 IFN in vivo. lt is yet to be 
established whether this is also associated with increased 
expression of MHC and adhesion molecules. Moreover, 
one must somehow reconcile these latter Observations and 
those presented in the present study, with the knowledge 
that in subacute sderosing panencephalitis, there appears 
tobe no particular defect in MV T cell responses, that there 
is often abundant nucleocapsid protein present in infected 
CNS cells, and yet the virus is not effectively eliminated 
[46). 
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